Leukemia, Lymphoid: all 1,772 studies
Page 8 of 18. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.
- CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/LymphomaWithdrawnNCT05613348Phase 1/2
- Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 2
- Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALLStatus unknownNCT05578378Phase 2/3
- Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALLWithdrawnNCT05571540Phase 1/2
- Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic LeukemiaCompletedNCT05563545Phase 1
- Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALLCompletedNCT05557110Phase 2
- Cardiotoxicities in Patients Receiving BTKiWithdrawnNCT05521178
- STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnNCT05519527Phase 1
- Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/LymphomaWithdrawnNCT05487495Phase 1
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT05480501Early Phase 1
- Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLLWithdrawnNCT05465876Phase 2
- Information Support Using an Online Learning Platform for Malaysian Pediatric Leukemia and Lymphoma ParentsCompletedNCT05455268Not applicable
- Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in PediatricStatus unknownNCT05428111Not applicable
- Family-Based Behavioral Treatment for Childhood Survivors of Acute Lymphoblastic LeukemiaTerminatedNCT05410574Not applicable
- Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLTerminatedNCT05360238Phase 1/2
- First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic MalignanciesTerminatedNCT05348889Phase 1/2
- Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic LeukemiaStatus unknownNCT05326984Not applicable
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
- Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic LeukemiaCompletedNCT05316831Phase 4
- A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic LeukemiaTerminatedNCT05292898Phase 1
- Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesCompletedNCT05290155Phase 1
- Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
- A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLLTerminatedNCT05272813Phase 1/2
- Phase I Study of JWCAR029 in Subjects With R/R CLL/SLLWithdrawnNCT05259813Phase 1
- Comparative Quantification of MTX and Its Metabolites Post GlucarpidaseCompletedNCT05250869
- A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT05244070Phase 1
- Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsCompletedNCT05225584Phase 1
- To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.Status unknownNCT05223686Phase 1
- Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerApproved for marketingNCT05172700
- CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic LeukemiaWithdrawnNCT05168748Phase 1
- Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyStatus unknownNCT05154474
- Pneumococcal Vaccination in Patients With Chronic Lymphocytic LeukaemiaStatus unknownNCT05145101
- Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRDStatus unknownNCT05137860Phase 4
- Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT05133310Phase 4
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- CAR20.19.22 T-cells in Relapsed, Refractory B-cell MalignanciesTerminatedNCT05094206Phase 1
- Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic LeukaemiaCompletedNCT05093192Not applicable
- Belimumab in Patients with Chronic Lymphocytic LeukemiaActive, not recruitingNCT05069051Phase 2
- Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCTStatus unknownNCT05066958Phase 1/2
- Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
- Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia AdultsStatus unknownNCT05059847Not applicable
- Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic LeukemiaCompletedNCT05045443Phase 2
- XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic LeukemiaTerminatedNCT05038644Phase 1
- EFFECT OF TREADMILL TRAINING ON BALANCE AFTER CHEMOTHERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIACompletedNCT05032716Not applicable
- Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic LeukemiaTerminatedNCT05032599Phase 1
- A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALLStatus unknownNCT05026229Not applicable
- A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALLStatus unknownNCT05024357Not applicable
- Vaccine Responsiveness in Patients With Chronic Lymphocytic LeukemiaCompletedNCT05007860
- HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALLTerminatedNCT05006040Early Phase 1
- A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter SyndromeTerminatedNCT04978779Phase 1
- Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaCompletedNCT04964908
- Exercise Training to Promote Resilience to Chronic Lymphocytic LeukemiaCompletedNCT04950452Not applicable
- JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived AsparaginaseApproved for marketingNCT04943952
- Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesStatus unknownNCT04934774Phase 1
- Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaStatus unknownNCT04916860Not applicable
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsCompletedNCT04888468Phase 1
- Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALLStatus unknownNCT04888442Phase 1
- Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLLCompletedNCT04883749Phase 2
- A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBLWithdrawnNCT04860817Early Phase 1
- Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04852822
- Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
- Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies MalignanciesStatus unknownNCT04823091Phase 1
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT04806035Phase 1
- Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological MalignanciesStatus unknownNCT04796688Phase 1
- Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALLCompletedNCT04788472Phase 2
- Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationWithdrawnNCT04781855Phase 1
- Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapyActive, not recruitingNCT04778579Phase 2
- Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic LeukemiaCompletedNCT04774744Not applicable
- Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic LeukemiaCompletedNCT04770922
- Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT04754035Phase 2
- Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALLStatus unknownNCT04740203Phase 1/2
- Dual Target CAR-T Cells in B-cell Acute Lymphoblastic LeukemiaStatus unknownNCT04723901Phase 1/2
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
- Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)CompletedNCT04716075Phase 2
- Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaStatus unknownNCT04714593Phase 1/2
- Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT04699162
- A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaWithdrawnNCT04694560
- Anakinra in Previously Untreated Chronic Lymphocytic Leukemia PatientsStatus unknownNCT04691765Phase 1
- the Efficacy and Safety of CLAE in R/R T-ALL/LBLStatus unknownNCT04679506
- Evaluation of Long-term Health Status and Quality of Life in Adult Survivors With Philadelphia-negative Acute Lymphoblastic Leukemia/Lymphoma Treated With an Intensive Pediatric or Pediatric-inspired ProtocolStatus unknownNCT04677231
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
- Study of Oral Venetoclax Tablets in Combination With Intravenous Obinutuzumab Injection to Assess Achievement of Best Response in Adult Participants With Chronic Lymphocytic LeukemiaTerminatedNCT04655261
- CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)Status unknownNCT04653493Phase 1
- Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsStatus unknownNCT04640909Not applicable
- Intermittent Fasting and CLL/SLLCompletedNCT04626843Phase 1
- CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04626765Early Phase 1
- Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT04626726Early Phase 1
- GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALLTerminatedNCT04601584Phase 1/2
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T CellsCompletedNCT04572308Phase 1
- MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaNo longer availableNCT04559555
- TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)CompletedNCT04557436Phase 1
- Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)CompletedNCT04554485Phase 2
- Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALLTerminatedNCT04554459Phase 2
- Assesment of JL1 Expression in Acute LeukemiaStatus unknownNCT04554381Phase 1
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
- Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLLStatus unknownNCT04502394Phase 1/2
- Vitamin D and Methotrexate Adverse EffectsStatus unknownNCT04488237
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1